[an error occurred while processing this directive] | [an error occurred while processing this directive]
Distribution of residual cancer cells in bowel wall and its associated factors in patients with rectal cancer after preoperative VMAT with concurrent chemotherapy
Xiao Lin, Deng Wenjing, Huang Rong, Zhou Guanqun, Xiao Weiwei, Chen Li, Qiu Bo, Chang Hui, Gao Yuanhong, Liu Mengzhong
*Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Abstract Objective To investigate the distribution of residual cancer cells (RCCs) in the bowel wall and its associated factors among patients with rectal cancer after preoperative volumetric modulated arc therapy (VMAT) with concurrent chemotherapy. Methods A retrospective analysis was performed on the clinical data of 178 patients with locally advanced rectal cancer who received VMAT with concurrent chemotherapy followed by surgery in our hospital from April 2011 to April 2013. There were 124 males and 54 females,and the age range was from 23 to 84 years.T1, T2, T3, and T4 rectal cancer was found in 1, 2, 73, and 102 patients, respectively. All the RCCs in surgical specimens from different layers of the bowel wall were evaluated pathologically. Between-group differences were evaluated by Fisher′s exact test, and the associations of preoperative T and N stages with postoperative ypT and distribution of RCCs in the bowel wall were determined by Spearman rank correlation test. Results The rates of RCCs in the mucosa, submucosa, muscularis propria, and subserosa/perirectal fat surgical specimens were 15.2%, 27.0%, 46.6%, and 46.1%, respectively, for all patients, and were 20.0%, 36.7%, 69.2%, and 68.3%, respectively, for 120 patients with ypT2-4 disease. Of all patients surgically treated, 52 had ypT0 disease, 2 had ypTis disease, 4 had ypT1 disease, 38 had ypT2 disease, 77 had ypT3 disease, and 5 had ypT4 disease. The rate of ypT0 in 36 ypN (+) patients was significantly lower than that in 140 ypN0 patients (3% vs. 35.7%, P=0.000), yet its rate of RCCs in the subserosa/perirectal fat wassignificantly higher than that in ypN0 patients (83% vs. 36.4%,P=0.000). The rate of ypT0 wassignificantly higher in 73 T3 patients than in 102 T4 patients(37% vs. 21.6%, P=0.025).Conclusions Most RCCs in the bowel wall of patients treated with preoperative VMAT with concurrent chemotherapy are distributed within or below the muscularis propria, which are significantly associated with ypT, ypN, and T stages.The value of biopsy for primary rectal lesions after neoadjuvant CRT may be very limited.
Xiao Lin*,Deng Wenjing,Huang Rong et al. Distribution of residual cancer cells in bowel wall and its associated factors in patients with rectal cancer after preoperative VMAT with concurrent chemotherapy[J]. Chinese Journal of Radiation Oncology, 2014, 23(3): 210-213.
Xiao Lin*,Deng Wenjing,Huang Rong et al. Distribution of residual cancer cells in bowel wall and its associated factors in patients with rectal cancer after preoperative VMAT with concurrent chemotherapy[J]. Chinese Journal of Radiation Oncology, 2014, 23(3): 210-213.
[1] Otto K. Volumetric modulated arc therapy:IMRT in a single gantry arc[J]. Med Phys,2008,35:310-317. [2] Edge SB, Byrd DR, Compton CC, et al. American jointcommittee on cancer (AJCC) cancer staging manual[M]. 7th ed. Chicago:Springer Inc,2010:143-164. [3] Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer:a radiation therapy oncology group consensus panel contouring atlas[J]. Int J Radiat Oncol Biol Phys,2009,74:824-830. [4] A phase Ⅱ evaluation of preoperative chemoradiotherapy utilizing intensity modulated radiation therapy (IMRT) in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer[DB/OL][2013-12-01].http://www.rtog.org/Clinical Trials/ProtocolTable/StudyDetails.aspx?study=0822. [5] Duldulao MP, Lee W, Streja L, et al. Distribution of residual cancer cells in the bowel wall after cancer[J]. Dis Colon Rectum,2013,56:142-149. [6] Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, et al. A large-scale candidate gene approachidentifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer[J]. Pharmacogenomics J,2011,11:437-443. [7] Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase Ⅱ trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer:preliminary results of the ACOSOG Z6041 trial[J]. Ann Surg Oncol,2012,19:384-391.
2014, Vol. 23 
